
Taiwan's Lotus Pharma inks $125 M deal with LENZ Therapeutics to commercialise presbyopia treatment
Taiwan's Lotus Pharma inks $125 M deal with LENZ Therapeutics to commercialise presbyopia treatment May 13, 2025 | Tuesday | News Exclusive license and commercialisation agreement for LNZ100 in the Republic of Korea and Southeast Asia image credit- …